• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Atogepant

CAS No. 1374248-81-3

Atogepant ( MK-8031;AGN-241689 )

产品货号. M11545 CAS No. 1374248-81-3

A potent, selective and orally available CGRP receptor antagonist for the prevention of migraine.

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
100MG 获取报价 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Atogepant
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    A potent, selective and orally available CGRP receptor antagonist for the prevention of migraine.
  • 产品描述
    A potent, selective and orally available CGRP receptor antagonist for the prevention of migraine.Migraine Phase 3 Clinical
  • 同义词
    MK-8031;AGN-241689
  • 通路
    GPCR/G Protein
  • 靶点
    CGRP Receptor
  • 受体
    CGRP Receptor
  • 研究领域
    Neurological Disease
  • 适应症
    Migraine

化学信息

  • CAS Number
    1374248-81-3
  • 分子量
    603.53
  • 分子式
    C29H23F6N5O3
  • 纯度
    >98% (HPLC)
  • 溶解度
    10 mM in DMSO
  • SMILES
    O=C(C1=CN=C2C(C[C@@]3(C4=CC=CN=C4NC3=O)C2)=C1)N[C@@H]5C(N(CC(F)(F)F)[C@H](C)[C@H](C6=C(F)C=CC(F)=C6F)C5)=O
  • 化学全称
    (3'S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

产品手册
关联产品
  • α-CGRP (human)

    Endogenous calcitonin gene-related peptide receptor (CGRP) agonist.

  • Adrenomedullin (11-5...

    Adrenomedullin 11-50 rat is a peptide fragment of adrenomedullin that possesses systemic vasodilator activity at the level of calcitonin gene-related peptide-1 (CGRP1) receptor activation. Adrenomedullin and its peptide may be used in bone growth studies.

  • Calcitonin(salmon) A...

    Calcitonin(salmon) Acetate, a calcium regulating hormone, is used to treat osteoporosis in women who are at least 5 years past menopause.Oral Calcitonin salmon treatment dose-dependently attenuates fasting and non-fasted hyperglycaemia during the intervention period.